Piroxicam
Based on 5 publication(s) in Google Scholar
Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.
For research use only. We do not sell to patients.
- Purity: 99.78%
- CAS No.: 36322-90-4
- Formula: C15H13N3O4S
- Molecular Weight:331.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Cardiotoxic Compound Library
HY-L225
Publications Citing Use of MedChemExpress (MCE) Piroxicam
More
Biological Activity
|
COX-2 25 μM (IC50, in human monocytes) |
COX-1 47 μM (IC50, in human monocytes) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
20.5 μM
Compound: Piroxicam
|
TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
|
[PMID: 10991954] |
| THP-1 | IC50 |
>20 μM
Compound: Piroxicam
|
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced TNF-alpha secretion incubated for 2 hrs prior to PMA challenge measured after 48 hrs by ELISA
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced TNF-alpha secretion incubated for 2 hrs prior to PMA challenge measured after 48 hrs by ELISA
|
[PMID: 24531227] |
| THP-1 | IC50 |
18 μM
Compound: Piroxicam
|
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 2 hrs followed by PMA challenge measured after 48 hrs by ELISA
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 2 hrs followed by PMA challenge measured after 48 hrs by ELISA
|
[PMID: 24780595] |
| THP-1 | IC50 |
18.1 μM
Compound: Piroxicam
|
Anti-inflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta production after 48 hrs by ELISA
Anti-inflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta production after 48 hrs by ELISA
|
[PMID: 26748696] |
| THP-1 | IC50 |
21.33 μM
Compound: Piroxicam
|
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA
|
[PMID: 23811092] |
Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively[1]. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 36322-90-4
-
Appearance Solid
-
Molecular Weight 331.35
-
Formula C15H13N3O4S
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(O)C2=CC=CC=C2S(N1C)(=O)=O)NC3=NC=CC=C3
-
Synonyms
CP-16171
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Chem Biol Interact
Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. [Abstract]2021 Apr 1:338:109425. PMID: 33617802 -
Eur J Pharm Biopharm
Bupivacaine multivesicular liposomes/meloxicam nanocrystals in a thermosensitive gel adapted to the "microenvironment" for long-term analgesia. [Abstract]2025 Jan 10:114630. PMID: 39800191 -
bioRxiv
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. [Abstract]2026 Apr 18:2026.04.17.719256. PMID: 42039650
Solvent & Solubility
DMSO : 50 mg/mL (150.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Urinary bladder cancer cell lines are treated with graded concentrations of carboplatin (0.05, 0.5 and 1 μM) and Piroxicam (CP-16171) (167, 333 and 500 μM) for 72 h to assess dose-response profiles. For the combination approach, 0.05 μM of carboplatin is used with 333 μM Piroxicam. Both drugs are freshly prepared before each experiment. An untreated control group (cells not exposed to carboplatin and Piroxicam) is used for all assays[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Dogs[2]
Dogs undergo tumor staging, including thoracic and abdominal radiography, cystography, ultrasonography, and cystoscopy (with collection of tissue samples) before treatment and after 4 weeks of Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p. o.) treatment. Dogs receive no other cancer treatment during the 4 weeks of Piroxicam (CP-16171) treatment. Tissue samples are immediately frozen in liquid nitrogen for PGE2 analysis or fixed in 10% neutral buffered formalin for immunohistochemical examination. Urine is also collected before and after Piroxicam treatment, aliquoted, and then stored at −80°C until analyzed[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85. [Content Brief]
[2]. Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62(2):356-8. [Content Brief]
[3]. Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37(4):1737-1745. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0180 mL | 15.0898 mL | 30.1796 mL | 75.4489 mL |
| 5 mM | 0.6036 mL | 3.0180 mL | 6.0359 mL | 15.0898 mL | |
| 10 mM | 0.3018 mL | 1.5090 mL | 3.0180 mL | 7.5449 mL | |
| 15 mM | 0.2012 mL | 1.0060 mL | 2.0120 mL | 5.0299 mL | |
| 20 mM | 0.1509 mL | 0.7545 mL | 1.5090 mL | 3.7724 mL | |
| 25 mM | 0.1207 mL | 0.6036 mL | 1.2072 mL | 3.0180 mL | |
| 30 mM | 0.1006 mL | 0.5030 mL | 1.0060 mL | 2.5150 mL | |
| 40 mM | 0.0754 mL | 0.3772 mL | 0.7545 mL | 1.8862 mL | |
| 50 mM | 0.0604 mL | 0.3018 mL | 0.6036 mL | 1.5090 mL | |
| 60 mM | 0.0503 mL | 0.2515 mL | 0.5030 mL | 1.2575 mL | |
| 80 mM | 0.0377 mL | 0.1886 mL | 0.3772 mL | 0.9431 mL | |
| 100 mM | 0.0302 mL | 0.1509 mL | 0.3018 mL | 0.7545 mL |
Powered by Bioz